Product
BCD-178
Aliases
pertuzumab
2 clinical trials
1 indication
Indication
Breast CancerClinical trial
A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy VolunteersStatus: Active (not recruiting), Estimated PCD: 2023-04-30
Clinical trial
A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast CancerStatus: Recruiting, Estimated PCD: 2024-01-22